In ER-/PR-/HER2- breast cancer patients, high miR-200b-3p and miR-190a along with low miR-512-5p levels in core biopsy was predictive of better response to neoadjuvant chemotherapy [140]. The gene discussed is ERBB2; the disease is breast carcinoma.